ERBB2 and neoplasm: An efficient, genetically engineered bispecific antibody (BsAb) was developed in previous years, which utilizes a combination of antibodies targeting the surface of T cells (cluster of differentiation; CD3) and tumor surface antigens (epithelial cell adhesion molecule, CD19 and HER2) (18).